Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income	$ 2,346	$ 958
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	393	351
Impairment of intangible assets	0	404
Release of accounts payable no longer owed		(406)
Deferred income taxes	(823)
Change in fair value of derivative liability	427	64
Accretion of financing instruments and amortization of prepaid financing costs	105	192
Compensation expense on employee stock options	49	31
Impairment charge on investment in iBio, Inc.	36
Allowance for doubtful accounts	(1)	30
Gain on disposal of fixed assets		(15)
Changes in operating assets and liabilities:
Accounts receivable	(884)	(527)
Inventories	111	(1,978)
Prepaid expenses and other assets	(43)	(99)
Accounts payable	(1,292)	727
Accrued expenses and other current liabilities	(27)	(326)
Net cash provided by (used in) operating activities	397	(594)
Cash flows from investing activities:
Purchase of property and equipment	(327)	(109)
Proceeds from sale of fixed assets		2
Net cash used in investing activities	(327)	(107)
Cash flows from financing activities:
Advances under revolving credit facility	45,385	41,166
Repayments of advances under revolving credit facility	(44,919)	(41,418)
Proceeds from sale/lease back	158
Proceeds from exercises of stock options	3
Proceeds from Line of Credit Note		43
Repayments under term notes payable	(829)	(620)
Repayments under capitalized lease obligations	(131)	(121)
Proceeds from term note payable		1,975
Net cash (used in) provided by financing activities	(333)	1,025
Net (decrease) increase in cash	(263)	324
Cash at beginning of fiscal year	395	71
Cash at end of fiscal year	132	395
Supplemental disclosures of cash flow information:
Interest	884	745
Income taxes	366	168
Supplemental disclosures of non-cash transactions:
Accretion of discount on Convertible Note Payable	39	86
Financing on capitalized lease obligations		$ 317